DavidMWeinstockMD

PubMed

• Leukemia circulation kinetics revealed through blood exchange method.
  Alex B Miller, Felicia H Rodriguez, Adam Langenbucher, Lin Lin, Christina Bray, Sarah Duquette, Ye Zhang, Dan Goulet, Michael T Hemann, Scott R Manalis, Andrew A Lane,...> ;Communications Biology. 2024 Apr 20
• Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts.
  Olesinski, E., Bhatia, K., Wang, C., Pioso, M., Lin, X., Mamdouh, A., Ng, S., Sandhu, V., Jasdanwala, S., Yilma, B., Bohl, S., Ryan, J., Malani, D., Luskin, M., Kallio...> ;Blood Cancer Discovery. 2024 Mar 4
• Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma.
  Danmei Xu, Findlay Bewicke-Copley, Karina Close, Jessica Okosun, Robert Peter Gale, Jane Apperley, David M Weinstock, Hans-Guido Wendel, Jude Fitzgibbon> ;Blood Cancer Journal. 2024 Feb 13
• Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1.
  Adrian Schwarzer, Matheus Oliveira, Marc-Jens Kleppa, Scott D Slattery, Andy Anantha, Alan Cooper, Mark Hannink, Axel Schambach, Anneke Dörrie, Alexey Kotlyarov, Matth...> ;Molecular Cancer Therapeutics. 2023 Nov 1
• 1 citations
  TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence.
  Gongwei Wu, Noriaki Yoshida, Jihe Liu, Xiaoyang Zhang, Yuan Xiong, Tayla B Heavican-Foral, Elisa Mandato, Huiyun Liu, Geoffrey M Nelson, Lu Yang, Renee Chen, Katherine...> ;Science Translational Medicine. 2023 Sep 20
• 3 citations
  PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma.
  Tim Wartewig, Jay Daniels, Miriam Schulz, Erik Hameister, Abhinav Joshi, Joonhee Park, Emma Morrish, Anuroop V Venkatasubramani, Filippo M Cernilogar, Frits H A van He...> ;Nature Cancer. 2023 Oct 1
• Leukemia circulation kinetics revealed through blood exchange method.
  Alex B Miller, Adam Langenbucher, Felicia H Rodriguez, Lin Lin, Christina Bray, Sarah Duquette, Ye Zhang, Dan Goulet, Andrew A Lane, David M Weinstock, Michael T Heman...> ;Biorxiv. 2023 Sep 5
• 2 citations
  Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.
  Cristina Mastini, Marco Campisi, Enrico Patrucco, Giulia Mura, Antonio Ferreira, Carlotta Costa, Chiara Ambrogio, Giulia Germena, Cinzia Martinengo, Silvia Peola, Ines...> ;Science Translational Medicine. 2023 Jun 28
• 1 citations
  New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.
  Matthew L Arwood, Yao Liu, Shannon K Harkins, David M Weinstock, Lei Yang, Kristen E Stevenson, Olivia D Plana, Jingyun Dong, Haley Cirka, Kristen L Jones, Anniina T V...> ;Cell Chemical Biology. 2023 Jun 15
• 1 citations
  ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas.
  Baishan Jiang, David M Weinstock, Katherine A Donovan, Hong-Wei Sun, Ashley Wolfe, Sam Amaka, Nicholas L Donaldson, Gongwei Wu, Yuan Jiang, Ryan A Wilcox, Eric S Fisch...> ;Cell Chemical Biology. 2023 Apr 20
• Assessment of added activity of an antitumor agent.
  Cong Chen, Linda Zhiping Sun, Yixin Ren, Eric H Rubin, David M Weinstock, Emmett V Schmidt> ;Contemporary Clinical Trials. 2022 Dec 1
• 9 citations
  Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
  Wenchao Wu, Geoffrey M Nelson, Raphael Koch, Katherine A Donovan, Radosław P Nowak, Tayla B Heavican-Foral, Ajit J Nirmal, Huiyun Liu, Lei Yang, Jessica Duffy, Foster ...> ;Blood. 2022 Mar 31
• 3 citations
  The molecular ontogeny of follicular lymphoma: gene mutations succeeding the BCL2 translocation define common precursor cells.
  Sarah Haebe, William Keay, Stefan Alig, Anne-Wiebe Mohr, Larissa K Martin, Michael Heide, Ramona Secci, Stefan Krebs, Helmut Blum, Andreas Moosmann, Abner Louissaint J...> ;British Journal of Haematology. 2022 Mar 1
• 9 citations
  A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia.
  Harada, T., Heshmati, Y., Kalfon, J., Perez, M., Xavier Ferrucio, J., Ewers, J., Hubbell Engler, B., Kossenkov, A., Ellegast, J., Yi, J., Bowker, A., Zhu, Q., Eagle, K...> ;Genes & Development. 2022 Mar 1
• 54 citations
  Phase II biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
  Alison J. Moskowitz, Paola Ghione, Eric D. Jacobsen, Jia Ruan, Jonathan H. Schatz, Sarah J. Noor, Patricia L. Myskowski, Santosha A. Vardhana, Nivetha Ganesan, Helen H...> ;Blood. 2021 Oct 19
• 32 citations
  Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis.
  Katsuhiro Togami, Sun Sook Chung, Vikas Madan, Christopher A G Booth, Christopher M. Kenyon, Lucia Cabal-Hierro, Justin Taylor, Sunhee S. Kim, Gabriel K. Griffin, Mahm...> ;Cancer Discovery. 2021 Oct 6
• 12 citations
  Primary Cytotoxic T Cell Lymphomas Harbor Recurrent Targetable Alterations in the JAK-STAT Pathway.
  , , , , , , , , , , , , , , , , , , , , , > ;Blood. 2021 Aug 25
• 3 citations
  Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia
  Barry M. Zee, Kamrine E. Poels, Cong-Hui Yao, Kimihito Cojin Kawabata, Gongwei Wu, Cihangir Duy, William D. Jacobus, Elizabeth Senior, Jennifer E. Endress, Ashwini Jam...> ;Iscience. 2021 May 25
• 8 citations
  Low-cost transcriptional diagnostic to accurately categorize lymphomas in low- and middle-income countries.
  Fabiola Valvert, Oscar Silva, Elizabeth Solórzano-Ortiz, Maneka Puligandla, Marcos Mauricio Siliézar Tala, Timothy Guyon, Samuel L. Dixon, Nelly López, Francisco López...> ;Blood Advances. 2021 May 25
• 18 citations
  Author Correction: IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells.
  Jaewoong Lee, Mark Robinson, Ning Ma, Dewan Artadji, Mohamed A. Ahmed, Gang Xiao, Teresa Sadras, Gauri Deb, Janet Winchester, Kadriye Nehir Cosgun, Huimin Geng, Lai N....> ;Nature. 2021 Apr 1
• 21 citations
  Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features
  Xiaolong Alan Zhou, Jingyi Yang, Kimberly G. Ringbloom, Maria Estela Martinez-Escala, Kristen E. Stevenson, Alexander Wenzel, Damiano Fantini, Haley K. Martin, Andrea ...> ;Blood Advances. 2021 Feb 9
• 5 citations
  RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia
  David Koschut, Debleena Ray, Zhenhua Li, Emanuela Giarin, Jürgen Groet, Ivan Alić, Shirley Kow-Yin Kham, Wee Joo Chng, Hany Ariffin, David M. Weinstock, Allen Eng Juh ...> ;Oncogene. 2021 Jan 28
• 66 citations
  Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
  Shruti Bhatt, Marissa S. Pioso, Elyse Anne Olesinski, Binyam Yilma, Jeremy Ryan, Thelma Mashaka, Buon Leutz, Sophia Adamia, Haoling Zhu, Yanan Kuang, Abhishek Mogili, ...> ;Cancer Cell. 2020 Dec 14
• 2 citations
  On Grieving for the Out-of-Practice.
  David M. Weinstock> ;The New England Journal of Medicine. 2020 Nov 4
• 40 citations
  IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells
  Jaewoong Lee, Mark Robinson, Ning Ma, Dewan Artadji, Mohamed A. Ahmed, Gang Xiao, Teresa Sadras, Gauri Deb, Janet Winchester, Kadriye Nehir Cosgun, Huimin Geng, Lai N....> ;Nature. 2020 Nov 4
• Join now to see all

Journal Articles

• Outcomes After Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma  
  Herrera AF, Rodig, SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Alyea EP, Budde LE, Chen R, Chen Y-B, Chan WC, Cutler CS, H..., Biol Blood Marrow Transplant, 1/1/2018
• Activity of the PI3K-delta,gamma inhibitor Duvelisib in a phase I trial and preclinical models of T-cell lymphoma  
  Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster ..., Blood, 1/1/2018
• Co-targeting JAK/STAT and mTORC1/ C2 signaling produces synergistic activity in Philadelphia chromosome�like acute B-cell lymphoblastic leukemia  
  Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Tai C, Cavazos A, Park E, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu S-C, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Ra..., Oncotarget, 1/1/2018
• An �off-the-shelf� fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies  
  Cooper M, Choi J, Staser K, Ritchey J, Niswonger J, Eckardt K, Rettig M, Wang B, Eissenberg L, Ghobadi A, Gehrs L, Prior J, Achilefu S, Miller C, Fronick C, O�Neal J, ..., Leukemia, 1/1/2018
• B-lymphoid transcriptional repression of the pentose phosphate pathway reveals a unique therapeutic vulnerability of B cell malignancies  
  Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Ernst T, Hochhaus A, Jumaa H, Jian..., Cell, 1/1/2018
• Genomic analyses identify recurrent PD-L1/PD-L2 structural variants in cutaneous diffuse large B-cell lymphomas  
  Zhou XA, Wenzel A, Louissaint A, Yang J, Martinez-Escala ME, Guitart J, Behdad A, Cerroni L, Weinstock DM, Choi J, J Invest Dermatol, 1/1/2018
• Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reac...  
  Chiaretti S, Messina M, Grammatico S, Piciocchi A, Fedullo AL, Di Giacomo F, Peragine N, Gianfelici V, Lauretti A, Bareja R, Martelli MP, Vignetti M, Apicella V, Vital..., Brit J Haematol, 1/1/2018
• Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models  
  Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, ..., Nat Commun, 1/1/2018
• RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice  
  Ng SY, Brown L, Stevenson KE, Aster JC, DeSouza T, Louissaint, Weinstock DM, Blood, 1/1/2018
• Assessment of CD52 expression in �Double-hit� and �Double-expressor� lymphomas: implications for clinical trial eligibility  
  Craig JW, Mina MJ, Crombie JL, LaCasce AS, Weinstock DM, Pinkus GS, Pozdnyakova O, PLoS One, 1/1/2018
• Parp3 promotes long-range end-joining in murine cells  
  Layer JV, Cleary JP, Brown AJ, Stevenson KE, Van Scoyk A, Morrow SN, Blasco RB, Karaca E, Meng F-L, Frock RL, Tivey T, Kim S, Fuchs H, Chiarle R, Alt FW, Roberts SA, W..., Proc Natl Acad Sci USA, 1/1/2018
• Targeting minimal residual disease: a path to cure?  
  Luskin M, Murakami MA, Manalis SR, Weinstock DM, Nature Reviews Cancer, 1/1/2018
• Clinicogenetic risk modeling in ATL  
  Yoshida N, Weinstock DM, Blood, 1/1/2018
• Escape from X-Inactivation Tumor Suppressor (EXITS) genes contribute to cancer sex bias  
  Dunford A, Weinstock DM, Savova V, Schumacher SE, Cleary JP, Yoda A, Sullivan TJ, Gimelbrant AA, Beroukhim R, Lawrence MS, Getz G, Lane AA, Nat Genet, 1/1/2017
• Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation  
  Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedma..., J Clin Onc, 1/1/2017
• Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia  
  Pikman Y, Alexe G, Roti G, Conway AS, Furman A, Lee AS, Place AE, Kim S, Saran C, Modiste R, Weinstock DM, Harris M, Kung AL, Silverman LB, Stegmaier K, Clin Cancer Res, 1/1/2017
• Anti-leukemic Activity of the TYK2 selective inhibitor NDI-031301 in T-cell Acute Lymphoblastic Leukemia  
  Akahane K, Li Z, Etchin J, Berezovskaya A, Gjini E, Masse CE, Miao W, Rocnik J, Kapeller R, Greenwoods JR, Tiv H, Sanda T, Weinstock DM, Look AT, Brit J Haematol, 1/1/2017
• Deletion of ribosomal protein genes is a common vulnerability in human cancer, particularly in concert with TP53 mutation  
  Ajore R, Raiser D, McConkey M, Joud M, Boidol B, Mar B, Saksena G, Weinstock DM, Armstrong S, Ellis SR, Ebert BL, Nilsson B, EMBO Mol Med, 1/1/2017
• PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA  
  Day TA, Layer JV, Cleary JP, Guha S, Stevenson KE, Tivey T, Kim S, Schinzel AC, Izzo F, Doench J, Root DE, Hahn WC, Price BD, Weinstock DM, Nature Commun, 1/1/2017
• Functional Proteogenomics Reveals Biomarkers and Therapeutic Targets in Lymphomas  
  Rolland DCM, Basrur V, Jeon YK, McNeil-Schwalm C, Fermin D, Conlon KP, Zhou Y, Ng SY, Tsou CC, Brown NA, Thomas DG, Bailey NG, Omenn GS, Nesvizhskii AI, Root DE, Weins..., Proc Natl Acad Sci, 1/1/2017
• Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase  
  Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, G..., Oncotarget, 1/1/2017
• Inhibition of USP10 induces degradation of oncogenic FLT3: a novel approach to therapy of leukemia  
  Weisberg EL, Schauer N, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Goghale PC, Ritorto MS, De Cesar V, Trost M, Christodoulou ..., Nat Chem Biol, 1/1/2017
• Constitutive Ras Signaling and Ink4a/Arf Inactivation Cooperate During the Development of B-ALL in Mice  
  Sewastianik T, Jiang M, Sukhdeo K, Patel SJ, Roberts K, Kang Y, Alduaij A, Dennis PS, Lawney B, Liu R, Song Z, Xiong J, Zhang Y, Lemieux ME, Pinkus G, Rich JN, Weinsto..., Blood Advances, 1/1/2017
• A Unique B-cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B-cell Lymphomas  
  Ryan RJ, Petrovic J, Rausch D, Zhou Y, Lareau C, Kluk MJ, Christie AL, Lee W, Tarjam D, Guo B, Donohue LK, Gillespie S, Nardi V, Hochberg EP, Blacklow SC, Weinstock DM..., Cell Reports, 1/1/2017
• PDX-MI: minimal information for patient-derived tumor xenograft models  
  Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, ..., Cancer Res, 1/1/2017
• Join now to see all

Books/Book Chapters

• Disaster Medicine: Comprehensive Principles and Practice 
  Chapter: Radiation accidents and the medical management of acute radiation injury 
  Page 545.0 - 579.0Hatchett RJ, Weinstock DM, Goans REEditors: Koenig and Schultz.Cambridge University Press, New York, NY2016
• Principles and Practices of Infectious Diseases 
  Chapter: Epstein-Barr Virus, Varicella-Zoster Virus and Human Herpes Viruses-6 and -8 
  Page 359.0 - 370.0Kamboj M, Weinstock DMEditors: Safdar A.Humana Press, New York, NY2011
• Multidrug-resistant tuberculosis 
  Chapter: Multidrug-resistant tuberculosis and the health care worker 
  Page 225.0 - 240.0Weinstock DM, Sepkowitz KAEditors: Bastian I, Portaels F.Kluwer Academic Publishers, Dordrecht, The Netherlands2000

Abstracts/Posters

• Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
  David M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell Malignancies
  David M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults
  David M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia
  David M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling
  David M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL
  David M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia
  David M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Future collaboration with CTCL
  Weinstock D, Cutaneous Lymphoma International Consortium Investigator Meeting, St. Gallen, Switzerland, 1/1/2018
• Join now to see all

Lectures

• Aggressive Lymphomas 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• What is the molecular basis and most promising road towards molecular targeted therapies for double-hit lymphoma? 
  Boston, MA - 1/1/2018
• Translocation models for T-cell lymphoma 
  Boston, MA - 1/1/2018
• Interrogating the xenograft microenvironment 
  Chicago, IL - 1/1/2018
• Functional approaches to target lymphomas 
  Scottsdale, AZ - 1/1/2018
• Defining and targeting vulnerabilities in T cell lymphomas 
  Philadelphia, PA - 1/1/2018
• Expert Stakeholder Panel on Innovative Financing 
  Washington, DC - 1/1/2018
• Genomics of T-cell lymphomas 
  San Diego, CA - 1/1/2018
• New Strategies for Cancer Translation 
  Rennes, France - 1/1/2018
• The Public Repository of Xenografts 
  University of Copenhagen, Copenhagen, Denmark - 1/1/2018
• Defining Vulnerabilities of PTCL 
  Bologna, Italy - 1/1/2018
• Co-Clinical Trials with PDX models 
  Stockholm, Sweden - 1/1/2018
• How to predict responses in silico and in vitro? 
  European School of Hematology, Saggart (Dublin), Ireland - 1/1/2018
• Approaches to advance precision medicine and immune-oncology in hematologic malignancies 
  Seville, Spain - 1/1/2018
• Forum on Patient-Derived Models: What�s Next 
  DFCI, Boston, MA - 1/1/2018
• Targeting vulnerabilities in lymphoid neoplasms 
  Waltham, MA, 2018; Boston University Medical Center, Boston, MA, 2018; Brigham and Women�s Hospital, - 1/1/2018
• Targeting vulnerabilities in high-risk lymphoid neoplasms 
  Waltham, MA - 1/1/2018
• Targeting Lymphomas with Sex, Drugs and Money 
  Division of Hematology/Oncology, MSKCC, New York, NY - 1/1/2017
• Curing Lymphoid Malignancies: Of Mice and Men 
  University of Texas MD Anderson Cancer Center, Houston, TX, 2017; Division of Hematology/Oncology, N - 1/1/2017
• Preclinical Models for Lymphoma Therapeutics Development 
  Dallas, TX - 1/1/2017
• Functional Assays to Select Therapeutics in Leukemia 
  Saxtons River, VT - 1/1/2017
• New approaches for targeting T-cell lymphomas 
  Atlanta, GA - 1/1/2017
• Assaying MRD with functional measurements of mass kinetics 
  Bethesda, MD - 1/1/2017
• New Strategies to Target Lymphoid Malignancies 
  Bart�s Cancer Institute, London, England - 1/1/2017
• New Financial Approaches to Support Access to Curative Therapeutics 
  Baveno, Italy - 1/1/2017
• Join now to see all

Other

• Modeling Human Immunity and Disease 
  Weinstock D, CellPress Webinar
  http://view6.workcast.net/register?cpak=6477842955389592&referrer=webinarpage
  1/1/2017
• Navigating Future Challenges in Lymphoma: A Map for the Road Ahead 
  LaCasce A, Weinstock DM, The Hematologist
  1/1/2015
• �Health care loans� for Hep C Cure 
  Andrew Lo, David Weinstock, Boston Globe
  1/25/2016
• Developing more efficient financing methods for healthcare is a matter of life and death 
  Andrew Lo, David Weinstock, Investment News
  1/23/2016
• State of the Art: Management of Rhodococcus equi infections [Perspectives, Contemporary Topics] 
  Weinstock DM, MD Consult Infectious Disease
  http://www.mdconsult.com
  1/26/2002
• State of the Art: Infections among Liver Transplant Recipients [Perspectives, Contemporary Topics] 
  Crawford CV, Weinstock DM, MD Consult Infectious Disease
  http://www.mdconsult.com
  1/28/2003
• Join now to see all